1. Home
  2. ADUS vs NNNN Comparison

ADUS vs NNNN Comparison

Compare ADUS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADUS
  • NNNN
  • Stock Information
  • Founded
  • ADUS 1979
  • NNNN 2021
  • Country
  • ADUS United States
  • NNNN Germany
  • Employees
  • ADUS N/A
  • NNNN N/A
  • Industry
  • ADUS Medical/Nursing Services
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ADUS Health Care
  • NNNN Health Care
  • Exchange
  • ADUS Nasdaq
  • NNNN Nasdaq
  • Market Cap
  • ADUS 2.0B
  • NNNN 2.2B
  • IPO Year
  • ADUS 2009
  • NNNN 2025
  • Fundamental
  • Price
  • ADUS $104.96
  • NNNN $42.80
  • Analyst Decision
  • ADUS Buy
  • NNNN
  • Analyst Count
  • ADUS 10
  • NNNN 0
  • Target Price
  • ADUS $143.50
  • NNNN N/A
  • AVG Volume (30 Days)
  • ADUS 130.7K
  • NNNN 147.4K
  • Earning Date
  • ADUS 08-04-2025
  • NNNN 01-01-0001
  • Dividend Yield
  • ADUS N/A
  • NNNN N/A
  • EPS Growth
  • ADUS 9.84
  • NNNN N/A
  • EPS
  • ADUS 4.42
  • NNNN 0.06
  • Revenue
  • ADUS $1,211,561,000.00
  • NNNN $8,185,146.00
  • Revenue This Year
  • ADUS $23.25
  • NNNN N/A
  • Revenue Next Year
  • ADUS $5.90
  • NNNN N/A
  • P/E Ratio
  • ADUS $23.77
  • NNNN $776.89
  • Revenue Growth
  • ADUS 11.38
  • NNNN 21.95
  • 52 Week Low
  • ADUS $88.96
  • NNNN $5.18
  • 52 Week High
  • ADUS $136.72
  • NNNN $55.65
  • Technical
  • Relative Strength Index (RSI)
  • ADUS 36.70
  • NNNN N/A
  • Support Level
  • ADUS $107.91
  • NNNN N/A
  • Resistance Level
  • ADUS $110.62
  • NNNN N/A
  • Average True Range (ATR)
  • ADUS 2.41
  • NNNN 0.00
  • MACD
  • ADUS -0.34
  • NNNN 0.00
  • Stochastic Oscillator
  • ADUS 5.46
  • NNNN 0.00

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: